Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Nektar Therapeutics (NKTR) Misses Q2 EPS by 3c
August 3, 2016 4:16 PM EDTNektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $32.77 million versus the consensus estimate of $30.47 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More